Navigation Links
Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Date:1/31/2008

SAN MATEO, Calif., Jan. 31 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. today announced it has entered into manufacturing agreements with Albemarle Corporation and Patheon Inc. The agreements provide for the large-scale clinical production of Varespladib (A-002), which is expected to be necessary in preparation for Anthera's Phase III clinical trials and planned New Drug Application submission to the Food and Drug Administration. Varespladib is Anthera's oral drug candidate for the treatment of cardiovascular disease.

Anthera believes the agreements position the company to:

-- Secure a cost-effective, long-term supply of Varespladib active

pharmaceutical ingredient (API) and tablets.

-- Quickly scale current manufacturing efforts to meet production

requirements, potentially accelerating Varespladib's time-to-market.

-- Reduce manufacturing related risks to the Varespladib clinical program.

-- Ensure a cost-effective transition to registration and commercial

production.

Building on the work done by Anthera's licensor, Eli Lilly, Albemarle will be responsible for process optimization and manufacture of cGMP quantities of the API. Patheon will be responsible for finished tablet production. The agreement also provides an option for the commercial production of Varespladib in the future. Financial terms were not disclosed.

"These agreements with Albemarle and Patheon provide Anthera with key supply chain resources for the manufacture of Varespladib," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals. "We are pleased to have secured outstanding technical organizations with significant commercial expertise that will contribute to the future success of the Varespladib program."

"We're delighted that Anthera has selected Albemarle as its API manufacturing supplier for its next phase of development," said David Clary, Albemarle Division V
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
6. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
7. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
8. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
11. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ... products from Teva Pharmaceuticals in connection with Teva,s acquisition ... own the ANDAs of fentanyl citrate lozenges, a generic ... version of Amrix®, as well as the U.S. rights ...
... 18, 2011 Tourists visiting the "Happiest Place on ... not able to experience it. Not all guests visiting ... walk the theme parks. Some people may appear healthy ... walking for long periods of time. Conditions stemming from ...
Cached Medicine Technology:Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals 2
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch ... and coolest mobile applications on the iOS, Android, and Windows ... NewsWatch, conducted the app review and shared with viewers how ... , The old saying goes, “A picture says a thousand ... can describe a single image, because each picture holds a ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
(Date:12/24/2014)... December 25, 2014 Over 700 toys, ... their local communities. That is 700 smiling little faces ... gift. Additionally over $6000 in monetary donations was given ... some of the expenses they incur through the year. ... were A Child's Haven , Shrine's Children's Hospitals, ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2
... , PROVO, Utah , Jan. 19 ... announced that it will release fourth quarter financial results prior to the ... Hunt , president and chief executive officer, will host a conference call ... a.m. (EDT) . During the call, participants can expect to hear management ...
... , ANN ARBOR, Mich. , ... and MEDITECH have collaborated to offer content from the Micromedex ... Care Information System (HCIS) — Emergency Department Management, Physician Care ... one of the Micromedex clinical evidence solutions from Thomson Reuters, ...
... , ATLANTA , Jan. 19 ... of the Unit of Interventional Radiology at the European Institute ... 2010 Best Poster Award by Dr. Shaun Samuels , ... Embolization Combined with Radiofrequency Ablation for Treating Complex Hepatic Tumors. ...
... health care, particularly at the end of life, may incite ... Hopkins emeritus professor of neurology called for the start of ... month,s issue of the Journal of Medical Ethics . ... Emeritus of Pediatric Neurology and a faculty member of the ...
... infection, researchers find , TUESDAY, Jan. 19 (HealthDay News) -- ... treatment for sickle cell disease, a common genetic disorder, new ... in the Journal of Clinical Investigation , are based ... with the disease will benefit from treatment with statins. ...
... chromosome component, research shows , TUESDAY, Jan. 19 (HealthDay ... of the reasons why omega-3 fatty acids are good for ... heart disease consumed, the slower their telomeres shrank. Telomeres are ... the more times a cell divides, making them a marker ...
Cached Medicine News:Health News:Nu Skin Enterprises to Announce Fourth Quarter and Annual 2009 Results 2Health News:Micromedex CareNotes Available Within the MEDITECH Health Care Information System 2Health News:Micromedex CareNotes Available Within the MEDITECH Health Care Information System 3Health News:Orsi Awarded First Place for Procedure with Embozene(TM) Microspheres 2Health News:Reasoning through the rationing of end-of-life care 2Health News:Shedding Light on Why Omega-3 Fatty Acids May Help the Heart 2Health News:Shedding Light on Why Omega-3 Fatty Acids May Help the Heart 3
0.3% Yeast Extract, 0.3% Malt Extract, 0.5% Peptone, and 1.0% Glucose....
Tryptone is the pancreatic digest of casein used as a nitrogen source for bacteria. Ideal for general bacteriological use with a variety of microorganisms. Tryptone is guaranteed BSE-Free....
Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
... units Penicillin/25,000 ug Streptomycin ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
Medicine Products: